Related by context. All words. (Click for frequent words.) 88 primary endpoint 80 primary endpoints 80 secondary endpoint 76 secondary endpoints 71 primary efficacy endpoints 71 secondary efficacy endpoints 70 efficacy endpoints 69 efficacy endpoint 68 prespecified 67 secondary efficacy endpoint 67 non inferiority 66 composite endpoint 65 demonstrated statistically significant 65 prospectively defined 65 noninferiority 65 Secondary endpoints included 65 Secondary endpoints 64 achieved statistical significance 64 ACR# response 63 statistically significant improvement 63 undetectable HCV RNA 62 desvenlafaxine succinate 62 evaluable 62 clinical endpoints 61 statistically significant reduction 61 Secondary endpoints include 61 mcg kg 61 mg dose 61 statistical significance 60 Secondary efficacy endpoints 60 timepoint 60 mg BID 60 CIMZIA TM 60 evaluable patients 60 placebo 59 tapentadol ER 59 Crohn Disease Activity 59 elagolix 59 clinically meaningful 59 Primary endpoints 59 pharmacodynamic 58 TLUS 58 oxycodone CR 58 retinal thickness 58 Montgomery Asberg Depression 58 virologic response 58 placebo p 58 MEND CABG II 58 mcg BID 58 serum phosphorus 58 chlorambucil 58 sUA 58 ALVESCO 58 lopinavir r 58 tumor progression TTP 58 Index CDAI 58 ribavirin RBV 58 Solid Tumors criteria 58 ACR# [002] 58 rolofylline 58 BENICAR HCT 58 p = #.# [002] 58 mcg QD 58 spontaneous bowel movements 58 sustained virologic response 58 placebo controlled 57 free survival PFS 57 Phase 2b study 57 ATACAND 57 mg QD 57 FEV1 57 plus dexamethasone 57 virologic failure 57 peginterferon alfa 2b 57 BENICAR 57 #mg/day [001] 57 mg kg dose 57 prespecified criteria 57 ACTEMRA TM 57 morphometric vertebral fractures 57 plus ribavirin 57 nasal symptom 57 Rating Scale MADRS 57 active comparator 57 #mg BID [001] 57 progression TTP 57 SVR# 57 cytogenetic response 57 median PFS 57 tolvaptan 57 HbA1c levels 57 creatinine clearance 57 gout flares 57 placebo p = 57 MADRS score 57 CSBM 56 Psoriasis Area 56 FOLFOX4 56 endoscopic remission 56 clinically meaningful improvement 56 CIMZIA TM certolizumab pegol 56 ug kg 56 teriflunomide 56 #mg/m# [002] 56 LEXIVA r 56 oral rivaroxaban 56 surrogate endpoint 56 #mg dose [003] 56 SPIRIT FIRST 56 dosage regimens 56 complete cytogenetic 56 pharmacokinetics PK 56 MADRS 56 TNSS 56 bosentan 56 viral kinetic 56 nab paclitaxel 56 REYATAZ r 56 #.#/#.# mmHg [001] 56 CR nPR 56 GOUT 56 NYHA functional class 56 HAMD 56 HAQ DI 56 neurologic progression 56 prospective multicenter randomized 56 statistically significant 56 KRN# 56 Scale EDSS 56 mcg dose 56 achieve statistical significance 55 Cmax 55 tolerated dose MTD 55 HbA1c 55 #mg BID [003] 55 Lupuzor ™ 55 peginterferon 55 LEVADEX 55 EURIDIS 55 PREZISTA r 55 certolizumab 55 #mg QD [001] 55 adalimumab 55 trough FEV1 55 Phase 2a trial 55 achieved PASI 55 posaconazole 55 GAMMAGARD 55 XIENCE V PROMUS Stent 55 glufosfamide 55 PASI scores 55 rapid virologic response 55 complete cytogenetic response 55 dose cohorts 55 #mg QD [002] 55 achieved ACR# 55 HDRS 55 4mg/kg 55 urinary N telopeptide 55 abacavir lamivudine 55 undetectable HBV DNA 55 demonstrated clinically meaningful 55 lopinavir r arm 55 candesartan cilexetil 55 mg kg 55 viral kinetics 55 peginterferon alfa 2a 55 Zerenex 55 chronic angina 55 primary hypercholesterolemia 55 elotuzumab 55 patients evaluable 55 LPV r 55 pharmacokinetic profile 55 postdose 55 alvimopan 55 rotigotine 55 CIMZIA ™ 55 randomized double 55 sunitinib 55 catheter occlusion 55 adjunctive placebo 55 statistical significance p 55 8mg/kg 55 apremilast 55 nonfatal MI 55 eplerenone 55 CDAI score 55 #mg/day [002] 55 pharmacokinetic PK 55 oral ridaforolimus 55 tipranavir 55 timepoints 55 HBeAg positive patients 55 headache nasopharyngitis 55 zonisamide SR 54 dose limiting toxicities 54 mucosal healing 54 azacitidine 54 tolerability 54 salmeterol fluticasone 54 mITT population 54 ACTEMRA 54 placebo controlled randomized 54 rALLy trial 54 Unified Parkinson Disease 54 RECIST criteria 54 placebo controlled clinical 54 multiple ascending dose 54 Pharmacokinetic parameters 54 CHAMPION PLATFORM 54 MAP# 54 mg TID 54 phase IIa 54 mcg albinterferon alfa 2b 54 HCV RESPOND 2 54 ACE inhibitor ramipril 54 LANTUS R 54 mg/m2 dose 54 Kaplan Meier analysis 54 binary restenosis 54 IPSS 54 limiting toxicity 54 dosing regimens 54 PANSS 54 unblinded 54 analgesic efficacy 54 reach statistical significance 54 abdominal pain abdominal discomfort 54 vandetanib 54 Thrombolysis 54 edoxaban 54 plasma uric acid 54 lispro 54 pharmacokinetic PK profile 54 nonrandomized 54 ACR# ACR# 54 baminercept 54 subcutaneously administered 54 CANCIDAS 54 iniparib 54 RECIST Response Evaluation Criteria 54 insulin detemir 54 double blind placebo 54 virologic 54 dosing cohort 54 ADAS cog 54 telaprevir dosed 54 QTcF 54 NATRECOR ® 54 HBeAg seroconversion 54 Negative Syndrome 54 dose escalation phase 54 peg interferon 54 serum urate 54 symptomatic VTE 54 Key secondary endpoints 54 Pegasys plus Copegus 54 certolizumab pegol 54 vidofludimus 54 HBeAg negative patients 54 P = .# 54 Azixa 54 Phase IIb clinical 54 hemoglobin A1c HbA1c 54 International Prostate Symptom 54 administered subcutaneously 54 detectable HCV RNA 54 randomization 54 irbesartan 54 recurrent glioblastoma multiforme 54 MEND CABG 54 Phase 2b clinical 54 Response Evaluation Criteria 54 DAS# CRP 54 inflammatory lesions 54 serum phosphorous 54 treatment emergent adverse 54 serum phosphate levels 54 randomized placebo controlled 54 ruboxistaurin 54 insulin glargine 54 SELENA SLEDAI score 54 Phase 2a clinical 54 1mg dose 54 XIENCE V demonstrated 54 lipid parameters 53 serum HBV DNA 53 Phase IIa 53 ≥ 53 pegylated interferon alfa 2b 53 oral methylnaltrexone 53 IIIa inhibitor 53 #mg/kg [002] 53 tanespimycin 53 refractory AML 53 Corlux 53 hyperphenylalaninemia HPA due 53 3mg/kg 53 QD dosing 53 virological response 53 FOLFIRI 53 R# #mg BID 53 serologically active patients 53 phase IIb clinical 53 plus methotrexate 53 levosimendan 53 tolterodine ER 53 pharmacodynamic PD 53 copies mL 53 prespecified secondary 53 post hoc 53 DSM IV criteria 53 bicifadine 53 #mg/m# [001] 53 NATRECOR R 53 lymphoma CTCL 53 log# IU mL 53 plus prednisone 53 diabetic neuropathic pain 53 dose escalation 53 mg d 53 PRIMO CABG2 53 ABC/3TC 53 CCyR 53 subanalysis 53 mRCC 53 NLX P# 53 imatinib therapy 53 Pegasys ® 53 VELCADE melphalan 53 pharmacokinetic PK study 53 Dextofisopam 53 FEV1 forced expiratory 53 ACR Pedi 53 rosuvastatin #mg 53 dosing regimen 53 randomized 53 p = #.# [004] 53 TACE 53 mcg mL 53 RE LY ® 53 colesevelam HCl 53 enoximone 53 noninferior 53 Chemophase 53 pegylated interferon peg IFN 53 evaluable subjects 53 incontinence episodes 53 Expanded Disability Status 53 atazanavir ritonavir 53 μg dose 53 PEG Interferon lambda 53 Adalimumab 53 ULORIC 53 Phase IIa trial 53 XIENCE V vs. 53 Phase IIa clinical 53 custirsen 53 aliskiren 53 GERD symptom 53 CDAI 53 NYHA Class III 53 Hb A1C 53 TIMI 53 death reinfarction 53 mg ustekinumab 53 target vessel revascularization 53 MIST II 53 adjuvant GIST 53 Randomized Evaluation 53 aprepitant 53 methotrexate MTX 53 pharmacokinetic characteristics 53 randomized Phase III 53 dimebon 53 q#h 53 multicenter randomized placebo controlled 53 STRIDE PD 53 Octreolin 53 plus COPEGUS 53 lumbar spine BMD 53 OMNARIS HFA 53 DAS# [002] 53 Study GL# 53 degarelix 53 Phase 1b 53 ADCS CGIC 53 nonresponders 53 tiotropium 53 varespladib 53 decitabine 53 PROMACTA 53 intermittent dosing 53 ancrod 53 LVEF 53 Sprycel dasatinib 53 UPDRS 53 NPH insulin 53 pharmacodynamics PD 53 HbA 1c 53 MoxDuo TM IR 53 reinfarction 53 angiographic outcomes 53 mg qd 53 Androxal TM 53 ORMD 53 QNEXA 52 TMC# C# 52 AeroLEF 52 tipranavir r 52 Solid Tumors RECIST 52 GSK# [001] 52 ACR# responses 52 ischemic cardiomyopathy 52 multicentre randomized 52 PEGylated anti 52 saline placebo 52 recurrent GBM 52 null responders 52 low dose cytarabine 52 AUA Symptom Score 52 CorVue ™ 52 PANSS total 52 #mg BID [002] 52 ARIXTRA 52 liver histology 52 EFAPROXYN 52 GnRH agonist 52 Alzheimer Disease Assessment 52 RAPAFLO R 52 HCV RNA 52 Proellex TM 52 randomized controlled 52 annualized relapse 52 comparator arm 52 #μg [002] 52 dosing cohorts 52 sustained virological response 52 μg kg 52 oral prodrug 52 Ostarine 52 placebo controlled Phase 52 log# 52 double blinded placebo 52 randomized Phase 2b 52 Phase 2a 52 IV bolus 52 budesonide 52 alteplase 52 fasting plasma glucose FPG 52 interferon gamma 1b 52 febrile neutropenia 52 melphalan prednisone 52 dosing interval 52 octreotide LAR 52 YMRS 52 Traficet EN 52 -#.# mg dL [002] 52 octreotide 52 docetaxel chemotherapy 52 CI -#.# 52 mL/min/#.# m2 52 PRECiSE 52 SBMs 52 Phase IIIb clinical 52 HIV RNA 52 Zenvia 52 pramlintide 52 PREZISTA r arm 52 ascending dose 52 cabazitaxel 52 statistically significant p = 52 APPRAISE 52 EDEMA3 52 monotherapy 52 iclaprim 52 systolic BP 52 riociguat 52 Ranolazine 52 ADAS Cog 52 mg BID dose 52 interferon alfa 52 fraction LVEF 52 temsirolimus 52 attain statistical significance 52 TRITON TIMI 52 cardiovascular hospitalization 52 aflibercept 52 ascending doses 52 FDA defined valvulopathy 52 BRIM2 52 ibandronate 52 eptifibatide 52 maximally tolerated dose 52 teduglutide 52 Phase Ib study 52 peg IFN 52 Perforomist Inhalation Solution 52 Welchol 52 HbA1C levels 52 Phase #b/#a clinical 52 IR prednisone 52 LIALDA 52 NEVO ™ 52 #.#g/day 52 tolerability profile 52 achieving PASI 52 atheroma volume 52 pramlintide metreleptin combination 52 PEG Intron 52 p = 52 cardiovascular morbidity 52 pharmacodynamic effects 52 clinically meaningful improvements 52 fondaparinux 52 5-FU/LV 52 serum HCV RNA 52 Durezol 52 orBec 52 #.#mg/dL 52 mapatumumab 52 everolimus eluting stents 52 severe exacerbations 52 â ‰ ¥ 52 evaluating Actimmune 52 APTIVUS r 52 undetectable viral load 52 randomisation 52 Fludara 52 bolus injection 52 belimumab 52 iloprost 52 remission CR 52 Phase 1a clinical 52 dosing 52 darusentan 52 infliximab 52 fasting plasma glucose 52 activated partial thromboplastin 52 Kaplan Meier estimate 52 dacarbazine 52 trials RCTs 52 BROVANA 52 INC# 52 placebo controlled clinical trials 52 systemic embolism 52 EOquin 52 COPEGUS 52 XOPENEX HFA 52 phase IIIb 52 eszopiclone 52 unresectable HCC 52 nodular partial response 52 Flu Cy 52 dose titration 52 blind placebo 52 infarct size 52 piperacillin tazobactam 52 clinically relevant 52 pharmacokinetic parameters 52 solifenacin 52 NIH CPSI 52 Severity Index PASI 52 CR CRu 52 randomized #:# 52 docetaxel Taxotere ® 52 Lucentis monotherapy 52 calculated creatinine clearance 52 Sustained virologic response 51 ZOLINZA 51 FOLPI 51 cangrelor 51 Montgomery Åsberg Depression 51 definite stent thrombosis 51 dose regimens 51 trospium 51 NYHA Class II 51 glycated hemoglobin levels 51 SSRI citalopram 51 % CI #.#-#.# [003] 51 hypogonadal men 51 biochemical recurrence 51 HCV SPRINT 51 canakinumab 51 QVA# 51 limiting toxicity DLT 51 disease progression TTP 51 ANCHOR trial 51 n = 51 randomized multicenter trial 51 mg/m2 51 velafermin 51 CLARITY study 51 bronchodilation 51 peginesatide 51 INCB# [001] 51 dose clopidogrel 51 sitaxsentan 51 Aclidinium 51 DAPT 51 Doxil ® 51 tirofiban 51 pulmonary exacerbations 51 A1c levels 51 DAS# remission 51 acute bronchospasm 51 mCRC patients 51 SIMPADICO 51 PEG IFN 51 olmesartan 51 REVLIMID lenalidomide 51 6R BH4 51 specified primary endpoint 51 cethromycin 51 dobutamine 51 HOMA IR 51 plus gemcitabine 51 Non inferiority 51 mg/# hr 51 Phase Ib 51 phase Ib 51 Tiotropium 51 g dL 51 plasma HCV RNA 51 HAM D# 51 achieve sustained virologic 51 blood Phe 51 mesalamine granules 51 Elitek 51 baseline HbA1c 51 apnea hypopnea index 51 IU ml 51 EDARBI 51 peginterferon alfa 2a #KD 51 tenofovir emtricitabine 51 blinded randomized 51 oral FTY# 51 OADs 51 lintuzumab 51 azilsartan medoxomil 51 WOMAC TM 51 TAXUS p value 51 Forodesine HCl 51 β blockers 51 metastatic castration resistant 51 Fibrillex TM 51 Brief Psychiatric 51 ARCOXIA 51 ZOMIG Nasal Spray 51 pharmacokinetic 51 Nesiritide 51 pegylated interferon alfa 2a 51 Phase IIB 51 Dacogen injection 51 worsening thrombocytopenia 51 valsartan 51 -#.# log# 51 Engerix B 51 VA# [002] 51 severe oral mucositis 51 DLTs 51 viral load 51 phase IIa clinical 51 mg/m2/day 51 relapsed MCL 51 lanthanum carbonate 51 prospective randomized controlled 51 INCB# [003] 51 acute HAE attacks 51 EmbraceAC 51 crizotinib PF # 51 Q#IR 51 PSA nadir 51 Aptivus ® 51 AEGR 51 Free Survival PFS 51 SABCS 51 Phenoptin 51 mcg doses 51 Phase IIb 51 glycoprotein IIb IIIa inhibitor 51 sirolimus 51 6MWD 51 unfractionated heparin UFH 51 CombAT 51 plasma concentrations 51 mg doses 51 HBV DNA levels 51 abatacept 51 DSMB 51 Phase 1a 51 serum uric acid 51 pertuzumab 51 glomerular filtration rate 51 GFT# 51 Capesaris 51 Ceplene/IL-2 51 NYHA class 51 methylnaltrexone 51 receiving golimumab 51 posttreatment 51 dosage regimen 51 Index CDAI score 51 CYPHER ® Stent 51 Median survival 51 amoxicillin clavulanate 51 FOLFOX 51 CIMZIA R 51 Apoptone 51 relapsed MM 51 mITT 51 univariate analysis 51 candesartan 51 moderate renal impairment 51 icatibant 51 phase 2a 51 postintervention 51 serum uric acid sUA 51 docetaxel 51 multicenter Phase 51 mL/min/#.# m 2 51 ispinesib administered 51 Contrave# 51 pharmacokinetic equivalence 51 doxorubicin docetaxel 51 pegylated interferon 51 mg administered orally 51 gadolinium enhancing lesions 51 romiplostim 51 carboplatin paclitaxel 51 serum testosterone 51 ELACYT 51 COMBIVIR 51 avosentan 51 IRLS 51 rizatriptan 51 xanthine oxidase inhibitor 51 Onrigin 51 bortezomib refractory 51 chemoradiation therapy 51 budesonide pMDI 51 Pemetrexed 51 pain palliation 51 fosbretabulin 51 symptom severity 51 Virulizin ® 51 evaluating REVLIMID 51 alfa 2a 51 LOVENOX 51 nasopharyngitis 51 PEGylated interferon beta 1a 51 dexamethasone 51 esomeprazole 51 mg RDEA# 51 CSBMs 51 nonsignificant 51 Elagolix 51 daily Infergen 51 Phase Ib clinical 51 hour bronchodilation 51 denufosol 51 single ascending dose 51 systemic corticosteroid 51 ARB telmisartan 51 eltrombopag 51 oblimersen 51 CRp 51 Cimzia TM 51 scores TNSS 51 ipsilateral stroke 51 phase IIb 50 Major Adverse Cardiac 50 Fibrin Pad 50 urate lowering therapy 50 corticosteroid dose 50 oral Xeloda 50 relapsed refractory multiple myeloma 50 Anturol TM 50 tecarfarin 50 VAPRISOL 50 subcutaneous SC 50 PRT# 50 esophageal candidiasis 50 bivalirudin 50 cEVR 50 PROTECT II 50 BoNTA 50 boosted protease inhibitor 50 Events MACE 50 dacarbazine chemotherapy 50 midstage study 50 Gabapentin GR 50 safety tolerability 50 trastuzumab emtansine T DM1 50 infusional 5-FU/LV 50 darunavir ritonavir 50 acutely decompensated congestive heart 50 TAXUS Stent 50 -#.# mg dL [001] 50 ribavirin USP 50 PRECISE 50 adefovir 50 YONDELIS 50 biologic therapy 50 SPIRIVA HandiHaler 50 COMFORT II 50 oral anticoagulant 50 PRE SURGE 50 statistically significant p 50 efficacy evaluable 50 MERLIN TIMI 50 partial remissions 50 ADHD RS 50 IOP lowering 50 LEXIVA 50 multicenter placebo controlled 50 Darusentan 50 Zemplar Capsules 50 Primary Endpoint 50 multicenter randomized 50 FFNS 50 TEAEs 50 idraparinux 50 DMARD 50 dose escalation study 50 thromboembolic events 50 ertapenem 50 MAGE A3 ASCI 50 KAPIDEX 50 Phase III ADT 50 pramipexole 50 briakinumab 50 relapsing multiple sclerosis 50 Aflibercept 50 pyrimidine nucleoside analog 50 Phase Ia 50 ritonavir boosted 50 left ventricular ejection 50 #μg [001] 50 mg dL 50 SYMMETRY trial 50 abciximab 50 lixisenatide 50 mTSS 50 safinamide 50 lumiliximab 50 cell lymphoma CTCL 50 KRAS mutations occur 50 tamsulosin 50 subcutaneous enoxaparin 50 Neuropsychiatric Inventory NPI 50 tezampanel 50 FROVA 50 PRIMO CABG 50 multicenter randomized double 50 Bronchitol 50 hours postdose 50 PSADT 50 randomized #:#:# 50 mg m² 50 Torisel 50 Sorafenib HCC Assessment 50 regorafenib 50 diameter stenosis 50 methacholine challenge 50 follicular NHL 50 ongoing Phase 1b 50 vernakalant 50 postmenopausal osteoporotic women 50 Multiple Ascending Dose 50 Score TOS 50 IFN alfa 50 Linagliptin 50 p = NS 50 dose escalation clinical 50 seropositive patients 50 remission induction 50 insulin degludec 50 CNS LS 50 IBDQ 50 Solid Tumours 50 prospective randomized multicenter 50 allopurinol 50 dyspnea 50 biphasic insulin aspart 50 MYDICAR 50 virologic response EVR 50 insulin lispro 50 heavily pretreated 50 statistically significant differences 50 pegylated interferon alpha 50 SinuNase 50 Laquinimod 50 serum potassium 50 linaclotide treated 50 Cloretazine 50 valacyclovir 50 metastatic hormone refractory 50 STELARA 50 corrected QT interval 50 FOLFOX6 50 posttransplant 50 ADAGIO study 50 PFO migraine 50 PegIFN RBV 50 β blocker 50 dyskinesia PD LID 50 recurrent ischemia 50 TAXUS Express Stent 50 fluticasone salmeterol 50 SCH # 50 Pred Forte 50 visilizumab 50 Val HeFT 50 dose escalation trial 50 Tarceva TM 50 Taxotere R 50 Board DSMB 50 recurrent genital herpes 50 events AEs 50 EDEMA4 trial 50 NSABP C 50 pegylated interferon alfa 50 cetrorelix pamoate 50 RECIST 50 clodronate 50 Peg IFN 50 GLP1 agonist 50 Xalatan R 50 cilostazol 50 stent binary restenosis 50 RESIST studies 50 splenectomized patients 50 vismodegib 50 mitoxantrone 50 TAXUS VI 50 Pain Intensity 50 phase IIb study 50 mGluR5 NAM 50 response CCyR 50 lubiprostone 50 oral diclofenac 50 achieved sustained virologic 50 randomized blinded 50 ILLUMINATE 50 lacosamide 50 FOLOTYN 50 Azedra 50 prospective multicenter 50 VIRAMUNE XR 50 Phase IIIb 50 Myocardial Infarction Study 50 Metabolic Efficiency 50 Pharmacokinetic 50 Score IPSS 50 formoterol fumarate 50 ng dL 50 cardiovascular hospitalizations 50 blinded randomized placebo controlled 50 titrated 50 fosamprenavir 50 AVOREN 50 oral renin inhibitor 50 keloid scarring 50 Subgroup analysis 50 NV1FGF 50 intravenous diuretics 50 beclomethasone dipropionate 50 hemoglobin A1c levels 50 8mg 50 undetectable virus HCV 50 forodesine 50 CTEPH 50 subcutaneous dose 50 ABSORB trial 50 L PPDS 50 atherothrombotic events 50 RLS symptoms 50 inhibitor RG# 50 #:# randomization 50 ticagrelor 50 maximal treadmill 50 vicriviroc 50 MCyR 50 randomized multicenter 50 INCB# [002] 50 statistically significant superiority 50 dose colchicine 50 rimonabant #mg 50 #mg [003] 50 protease inhibitor PI 50 prospectively stratified 50 pomalidomide 50 neostigmine 50 REMINYL ® 50 rFVIIa 50 % Confidence Interval 50 multicenter Phase III